| Name | Dantrolene sodium hemiheptahydrate |
| Description | Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1 and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction. Dantrolene sodium hemiheptahydrate (Sodium dantrolene) is the sodium salt form of dantrolene, a hydantoin derivative, and direct-acting skeletal muscle relaxant. |
| In vitro | Dantrolene sodium can inhibit intracellular Ca2+ release from the sarcoplasmic reticulum. In the linoleic acid emulsion system, Dantrolene sodium has strong antioxidant activity. |
| In vivo | In contrast of the slow soleus (SOL) muscle, Dantrolene sodium (5 mg/kg) has a greater inhibitory on the twitch contraction of the fast extensor digitorum longus (EDL) muscle. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 16.67 mg/mL (41.75 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 0.5 mg/mL (1.25 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Dantrolene sodium Hydrate | Dantrolene sodium hemiheptahydrate | Dantrolene sodium | CalciumChannel | Calcium Channel | Ca2+ channels | Ca channels | Autophagy |
| Inhibitors Related | Ethoxyquin | Kaolin | Aceglutamide | Allopurinol | Hemin | 2,4,6-Tri-tert-butylphenol | Guanidine hydrochloride | Hydroxychloroquine | Ethyl linoleate | Formamide | Paeonol | Alginic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |